Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 15738535

Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
J Clin Oncol
Publication date
2005 Jun 1
First author
Buzdar AU

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    J Clin Oncol. 2005 Jun 1;23(16):3656-9. doi: 10.1200/JCO.2005.10.910.
    note
    Source null
    related pmid
    15738533
    relationship
    Comment in
  2. citation
    J Clin Oncol. 2005 Sep 20;23(27):6803-4; author reply 6804-5. doi: 10.1200/JCO.2005.02.4406.
    note
    Source null
    related pmid
    16170195
    relationship
    Comment in
  3. citation
    J Clin Oncol. 2005 Oct 20;23(30):7759-60; author reply 7760-1. doi: 10.1200/JCO.2005.03.0213.
    note
    Source null
    related pmid
    16234551
    relationship
    Comment in

Authors and identifiers

  1. name
    Buzdar AU
    type
    Author
  2. name
    Ibrahim NK
    type
    Author
  3. name
    Francis D
    type
    Author
  4. name
    Booser DJ
    type
    Author
  5. name
    Thomas ES
    type
    Author
  6. name
    Theriault RL
    type
    Author
  7. name
    Pusztai L
    type
    Author
  8. name
    Green MC
    type
    Author
  9. name
    Arun BK
    type
    Author
  10. name
    Giordano SH
    type
    Author
  11. name
    Cristofanilli M
    type
    Author
  12. name
    Frye DK
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Buzdar AU
    type
    Author
  2. name
    Ibrahim NK
    type
    Author
  3. name
    Francis D
    type
    Author
  4. name
    Booser DJ
    type
    Author
  5. name
    Thomas ES
    type
    Author
  6. name
    Theriault RL
    type
    Author
  7. name
    Pusztai L
    type
    Author
  8. name
    Green MC
    type
    Author
  9. name
    Arun BK
    type
    Author
  10. name
    Giordano SH
    type
    Author
  11. name
    Cristofanilli M
    type
    Author
  12. name
    Frye DK
    type
    Author
bibliography ids
  1. nci-bib-c0453861224df5b6ae7ad835
book metadata
content sha256
59985f7fb4fc279496745b2af20db52cea028209c176d5df595b6e12b2ba140e
document type
citation
dois
  1. 10.1200/JCO.2005.07.032
electronic publication date
display
2005 Feb 28
precision
day
year
2005
evidence scope
bibliographic_metadata_only
id
pubmed:15738535
immutable id
pubmed:15738535@59985f7fb4fc279496745b2af20db52cea028209c176d5df595b6e12b2ba140e
journal
abbreviation
J Clin Oncol
issn electronic
Source null
issn print
0732-183X
issue
16
name
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
nlm unique id
8309333
pages
3676-85
volume
23
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    J Clin Oncol. 2005 Jun 1;23(16):3656-9. doi: 10.1200/JCO.2005.10.910.
    note
    Source null
    related pmid
    15738533
    relationship
    Comment in
  2. citation
    J Clin Oncol. 2005 Sep 20;23(27):6803-4; author reply 6804-5. doi: 10.1200/JCO.2005.02.4406.
    note
    Source null
    related pmid
    16170195
    relationship
    Comment in
  3. citation
    J Clin Oncol. 2005 Oct 20;23(30):7759-60; author reply 7760-1. doi: 10.1200/JCO.2005.03.0213.
    note
    Source null
    related pmid
    16234551
    relationship
    Comment in
outcomes validated
false
pmid
15738535
provenance
batch id
c1587c4840dc976b65de
provider
NCBI PubMed ESummary
record sha256
37595ad81707900b46d4112aa437bd18b6b60082de0e02dec1a097285a093f34
response sha256
1dc03bdea4f6d08d05f92b6e458fb2ffa8a3c523f1f3e268fece6307fc70dead
retrieved at
2026-09-09T23:45:59.852120+00:00
publication date
display
2005 Jun 1
precision
day
year
2005
publication types
  1. Clinical Trial
  2. Clinical Trial, Phase III
  3. Journal Article
  4. Randomized Controlled Trial
  5. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/15738535/
title
Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer.

Preserved source evidence · Not medical advice